Sunmax Biotechnology , Ltd. Overview
Valuation check: 4728.TWO's ROE is 56.71%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow56.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Sunmax Biotechnology , Ltd. (4728.TWO) currently reports a ROE of 56.71%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Sunmax Biotechnology , Ltd.'s ROE history and peer comparisons.
Sunmax Biotechnology , Ltd.'s ROE of 56.71% is higher than the Healthcare sector average of -75.59%. That is roughly 175.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Sunmax Biotechnology , Ltd.'s current 56.71% should be judged against Healthcare norms (sector average: -75.59%) and against 4728.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 56.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Sunmax Biotechnology , Ltd., and consider following 4728.TWO for alerts when major investors trade the stock.
Sunmax Biotechnology , Ltd. is classified in the Healthcare sector. On ROE, it currently shows 56.71% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4728.TWO with unrelated industries.
